Targeted Therapeutics Market Size, Growth, Demands Outlook and Forecasts to 2030

According to the research report, the global targetedtherapeutics market size is expected to touch USD 128 Billion by 2030, from USD 71.4 Billion in 2022, growing with a significant CAGR of 2.4% from 2022 to 2030. 

The targeted therapeutics report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global targeted therapeutics in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global targeted therapeutics market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global targeted therapeutics during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1358

 Scope of the Targeted Therapeutics Market

Report Highlights	Details
Market Size	USD 83.8 Billion by 2030
Growth Rate	CAGR 2.4% From 2021 to 2030
Largest Market	North America
Fastest Growing Market	Asia Pacific
Base Year	2021
Forecast Period	2021 to 2030
Segments Covered	Type, Application, Distribution Channel, Geography

This study covers a detailed segmentation of the global targeted therapeutics market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global targeted therapeutics market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

• Pfizer, Inc.
• AstraZeneca Plc.
• Amgen, Inc.
• F. Hoffmann-La Roche & Co.
• Genentech, Inc.
• Agenus, Inc.
• Celdara Medical LLC
• Arcus Biosciences, Inc.
• Aurinia Pharmaceuticals Inc.
• Gilead Sciences, Inc.
• Serena Therapeutics Inc.
• Nektar Therapeutics Inc.

Market Segmentation

 By Type

• Monoclonal Antibodies
• Small Molecule

By Application

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Renal Cancer
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
• Rest of the World

Research Methodology

The research methodology adopted by analysts for compiling the global targeted therapeutics report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global targeted therapeutics market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Targeted Therapeutics Market 

5.1. COVID-19 Landscape: Targeted Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Targeted Therapeutics Market, By Type

8.1. Targeted Therapeutics Market, by Type, 2021-2030

8.1.1. Monoclonal Antibodies

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Small Molecule

8.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Targeted Therapeutics Market, By Application

9.1. Targeted Therapeutics Market, by Application, 2021-2030

9.1.1. Breast Cancer

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Colorectal Cancer

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Lung Cancer

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Renal Cancer

9.1.4.1. Market Revenue and Forecast (2019-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Targeted Therapeutics Market, By Distribution Channel 

10.1. Targeted Therapeutics Market, by Distribution Channel, 2021-2030

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Targeted Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2019-2030)

11.1.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2019-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2019-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2019-2030)

11.2.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2019-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2019-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2019-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2019-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2019-2030)

11.3.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2019-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2019-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2019-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2019-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2019-2030)

11.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2019-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2019-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2019-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2019-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2019-2030)

11.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2019-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2019-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)

Chapter 12. Company Profiles

12.1. Pfizer, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. AstraZeneca Plc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Amgen, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. F. Hoffmann-La Roche & Co.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Genentech, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Agenus, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Celdara Medical LLC

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Arcus Biosciences, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Aurinia Pharmaceuticals Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Gilead Sciences, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

12.11. Serena Therapeutics Inc.

12.11.1. Company Overview

12.11.2. Product Offerings

12.11.3. Financial Performance

12.11.4. Recent Initiatives

12.12. Nektar Therapeutics Inc.

12.12.1. Company Overview

12.12.2. Product Offerings

12.12.3. Financial Performance

12.12.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com